SALL4 and chronic myelogenous leukemia, BCR-ABL1 positive: In the present study; as regard the re sponse to treatment; the cases with SALL4 gene expression > 1.0 RQ; showed CR in 19/29 (65.5%) > those with PR 5/8 (62.5%) > those who died before day 28 6/15 (40%), A study done by Shen et al., 2012, who found that the SALL4 expression level was increased in the AML group (median: 1.051; p=0.009), CML-BC group (median: 1.563; p=0.016) and the different AML subtypes M2 (median: 0.974; p=0.039), M3 (median: 0.799; p=0.083) and M5 (median1.465; p=0.026), it was lower in the M2-CR (median: 0.105; p=0.151) and M3-CR (median: 0.023; p=0.037) groups.